Xindian District

Researchers are evaluating the efficacy and safety of activated T lymphocytes ATL as a preventive immunotherapy for patients with hepatocellular carcinoma HCC who have undergone curative treatments. This open-label, single-arm, multicenter Phase II study focuses on patients with HCC stages I, II, or IIIa, following a specific enrollment ratio to reflect previous study results. The study aims to assess relapse-free survival over 12 months after treatment. Eligible patients receive ATL administered intravenously without premedication. The treatment schedule includes ten ATL infusions at Weeks 1, 2, 3, 4, 6, 8, 10, 14, 18, and 22. Administration for the first three patients is staggered to monitor safety, with a Data and Safety Monitoring Board reviewing adverse events after 10% of participants complete four doses. Participants provide peripheral blood at least 28 days before treatment to manufacture individualized ATL. Throughout the study, patients undergo various assessments including imaging CT or MRI, blood tests, liver and kidney function tests, and questionnaires evaluating quality of life and functional status. Safety monitoring includes tracking adverse events, laboratory values, vital signs, and physical examinations for up to 76 weeks. The primary outcome is relapse-free survival measured from first dosing to 12 months post-treatment.

Researchers are evaluating the safety of the HealiAid Collagen Wound Dressing in patients undergoing surgery for breast tumors, including both benign and malignant types with tumor sizes up to 5 cm. This open-label, multicenter, post-market clinical trial aims to record postoperative complications and adverse events, assess patient satisfaction and quality of life using the Breast-Q questionnaire, and monitor various health indicators such as vital signs, laboratory tests, tumor markers, breast ultrasonography, and mammography over a one-year period. During surgery, the tumor is completely removed with a 1-2 cm margin of healthy tissue, and the wound is cleaned before applying the HealiAid Collagen Wound Dressing. This soft, pliable dressing is adjusted to fit the wound size, using one to four pieces per wound, and remains in place until fully absorbed. Patients will follow standard postoperative rehabilitation protocols, including mobilization of the arm on the operated side shortly after surgery. Participants will be monitored closely during hospitalization for up to three days after surgery with continuous vital sign measurements. Follow-up visits occur at weeks 1, 2, 4, 12, 26, and 52 post-surgery, including wound assessments, adverse event monitoring, and breast appearance photographs at specified intervals. Breast ultrasonography is performed at weeks 2, 26, and 52, mammography at week 52, and laboratory tests including hematology and tumor marker assessments at week 26. Patient satisfaction and quality of life are evaluated before surgery and at multiple follow-up points using the Breast-Q questionnaire.

Cutaneous melanoma is the most aggressive form of skin cancer and is rare in Taiwan, with an incidence of about 1 in 100,000 people. This research focuses on acral lentiginous melanoma and mucosal melanoma, which are more common in Taiwan than in Caucasian populations and have distinct clinical and genetic features. These melanoma types in Asians often have higher recurrence rates after surgery, respond less to immunotherapy, and have shorter times without disease progression, leading to generally poor survival outcomes. The study observes patients with different stages of melanoma, including early-stage acral melanoma stage III, locally advanced acral melanoma stage III, resectable, advanced unresectable or metastatic melanoma stage IIIIV or recurrent, and those with advanced melanoma who have comprehensive genetic testing reports. Patients may provide tumor tissue samples for genetic analysis. The study tracks these groups to better understand the diseases progression and genetic alterations. Participants will be followed regularly for data collection, including tumor tissue analysis and medical history review. Researchers aim to evaluate how acral melanoma evolves over time in Taiwan. Patients are expected to have a life expectancy of more than three months and must be willing to provide tumor samples and comply with follow-up schedules. The study is observational and ongoing through December 2030.